NEW
YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group
Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2,"
the "Company" or "we") (NASDAQ: ANPC), a company with operations in
the United States and China focused on early cancer screening and
detection and entering into the operation of a business-to-business
e-commerce food platform focused on the sale of Asian sourced food
products, today announced that it filed its annual report on Form
20-F for the fiscal year ended December 31,
2022, with the U.S. Securities and Exchange Commission (the
"SEC") on May 16, 2023. The annual
report on Form 20-F can be accessed on the SEC's website
at http://www.sec.gov and the Company's investor
relations website at https://fresh2.co/investors.
About Fresh2 Group Limited
Fresh2 Group Limited is a biotechnology company focused on
early cancer screening and detection, with 155 issued patents as of
March 31, 2023. With two certified
clinical laboratories in China and
one CLIA and CAP accredited clinical laboratory in the United States, Fresh2 performs a suite of
cancer screening and detection tests, including CDA (Cancer
Differentiation Analysis), bio-chemical, immunological, and
genomics tests. The Company is entering the business-to-business
e-commerce food business with the formation of its wholly-owned
subsidiary Fresh2 Technology Inc and the acquisition of Fresh2
Ecommerce Inc.
For more information, please
visit: https://fresh2.co/investors.
For investor and media inquiries, please
contact:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-917-609-0333 (U.S.)
Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements are made under the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995 and are relating
to the Company's future financial and operating performance. The
Company has attempted to identify forward-looking statements by
terminologies including "believes," "estimates," "anticipates,"
"expects," "plans," "projects," "intends," "potential," "target,"
"aim," "predict," "outlook," "seek," "goal" "objective," "assume,"
"contemplate," "continue," "positioned," "forecast," "likely,"
"may," "could," "might," "will," "should," "approximately" or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
based on current expectations, assumptions and uncertainties
involving judgments about, among other things, future economic,
competitive and market conditions and future business decisions,
all of which are difficult or impossible to predict accurately and
many of which are beyond the Company's control. These statements
also involve known and unknown risks, uncertainties and other
factors that may cause the Company's actual results to be
materially different from those expressed or implied by any
forward-looking statement. Known and unknown risks, uncertainties
and other factors include, but are not limited to, our ability to
comply with Nasdaq Listing Rules including maintain our listing on
the Nasdaq Capital Market, the implementation of our business model
and growth strategies including our operation of a
business-to-business e-commerce food platform focused on the sale
of Asian sourced food products; trends and competition in the
cancer screening and detection market; our expectations regarding
demand for and market acceptance of our cancer screening and
detection tests and our ability to expand our customer base; our
ability to obtain and maintain intellectual property protections
for our CDA technology and our continued research and development
to keep pace with technology developments; our ability to obtain
and maintain regulatory approvals from the NMPA, the FDA and the
relevant U.S. states and have our laboratories certified or
accredited by authorities including the CLIA; our future business
development, financial condition and results of operations and our
ability to obtain financing cost-effectively; potential changes of
government regulations; general economic and business conditions in
China and elsewhere; our ability
to hire and maintain key personnel; our relationship with our major
business partners and customers; and the duration of the
coronavirus outbreaks and their potential adverse impact on the
economic conditions and financial markets and our business and
financial performance, such as resulting from reduced commercial
activities due to quarantines and travel restrictions instituted by
China, the U.S. and many other
countries around the world to contain the spread of the virus. A
number of these risks along with additional discussion of
forward-looking statements, are set forth in the Company's Annual
Report on Form 20-F and other reports filed with the Securities and
Exchange Commission. In addition, there is uncertainty about the
spread of the COVID19 virus and the impact it will have on the
Company's operations, global supply chains and economic activity in
general. Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these
forward-looking statements. In addition, these statements speak
only as of the date of this press release and, except as may be
required by law, the Company undertakes no obligation to revise or
update publicly any forward-looking statements for any reason.
.
View original
content:https://www.prnewswire.com/news-releases/fresh2-files-annual-report-on-form-20-f-for-fiscal-year-2022-301826558.html
SOURCE Fresh2 Group Limited